Table 3. Impacts of the classification using IL-6 and IL-1β levels on overall survival and progression-free survival in patients with gemicitabine monotherapy for advanced pancreatic cancer.
|
Overall survival | ||||
|---|---|---|---|---|
| IL-6/IL-1β classification | N | Median OS (95%CI) (days) | HR (95% CI) | P-value |
| IL-6Low/IL-1βLow |
25 |
306 (228–355) |
1 |
Ref. |
| IL-6Low/IL-1βHigh |
5 |
246 (97–346) |
1.48 (0.43–3.97) |
0.497 |
| IL-6High/IL-1βLow |
15 |
140 (83–334) |
1.90 (0.94–3.72) |
0.074 |
| IL-6High/IL-1βHigh | 15 | 79 (61–134) | 4.06 (1.96–8.18) | <0.001 |
|
Progression-free survival |
||||
|---|---|---|---|---|
| IL-6/IL-1β classification | N | Median PFS (95%CI) (days) | HR (95% CI) | P-value |
| IL-6Low/IL-1βLow |
25 |
158 (96–187) |
1 |
ref |
| IL-6Low/IL-1βHigh |
5 |
96 (42–229) |
1.68 (0.56–4.11) |
0.323 |
| IL-6High/IL-1βLow |
15 |
48 (23–92) |
2.24 (1.14–4.29) |
0.021 |
| IL-6High/IL-1βHigh | 15 | 46 (19–61) | 4.26 (2.08–8.55) | <0.001 |
Abbreviations: CI=confidence interval; HR=hazard ratio; IL=interleukin; OS=overall survival; PFS=progression-free survival.